1M7 Stock Chart & Stats
€0.34
>-€0.01(-0.57%)
At close: 4:00 PM EDT
€0.34
>-€0.01(-0.57%)
Day’s Range― - ―
52-Week Range€0.29 - €0.48
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€17.29M
Enterprise Value€15.04
Total Cash (Recent Filing)€582.00K
Total Debt (Recent Filing)€239.00K
Price to Earnings (P/E)―
Beta0.21
Next Earnings
May 05, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding54,037,327
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)4.06
Price to Sales (P/S)1.29
P/FCF Ratio-46.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€122.78K
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsConsistently high gross margins indicate that the company’s cognitive assessment software and related services have attractive underlying unit economics. If revenue scale improves, this margin profile could provide operating leverage, although current operating costs still prevent profitability.
Improved Balance-sheet ResilienceSubstantially lower debt and stronger equity improve financial resilience compared with 2023 and 2024. This reduces leverage-related pressure and gives management greater flexibility to support operations, invest in the platform, and withstand periods of uneven clinical-trial demand.
Cash-burn ReductionThe sharp reduction in operating and free-cash-flow outflows shows meaningful progress in cash control, even though the business remains cash-consuming. Sustaining this improvement would reduce funding pressure and move the company closer to becoming self-funding over time.
Bears Say
Persistent Operating And Net LossesFour consecutive years of operating and net losses show that the current revenue base has not yet supported the company’s cost structure. Persistent losses can constrain reinvestment, weaken financial flexibility, and make durable earnings growth dependent on stronger scale or further cost control.
Ongoing Negative Free Cash FlowAlthough cash burn improved substantially, negative free cash flow means the business is still not self-funding its operations and investment needs. Continued cash consumption may require tighter spending or external funding, limiting the resources available for expansion and product development.
Volatile And Declining Revenue BaseRevenue remains well below the 2023 peak and has been volatile, indicating that growth in the clinical-research business is not yet consistently compounding. An uneven revenue base makes fixed-cost absorption harder and increases the challenge of converting strong gross margins into operating profit.
Cambridge Cognition Holdings News
1M7 FAQ
What was Cambridge Cognition Holdings Plc’s price range in the past 12 months?
Cambridge Cognition Holdings Plc lowest stock price was €0.29 and its highest was €0.48 in the past 12 months.
What is Cambridge Cognition Holdings Plc’s market cap?
Cambridge Cognition Holdings Plc’s market cap is €17.29M.
When is Cambridge Cognition Holdings Plc’s upcoming earnings report date?
Cambridge Cognition Holdings Plc’s upcoming earnings report date is May 05, 2027 which is in 224 days.
How were Cambridge Cognition Holdings Plc’s earnings last quarter?
Cambridge Cognition Holdings Plc released its earnings results on Sep 16, 2026. The company reported -€0.019 earnings per share for the quarter.
Is Cambridge Cognition Holdings Plc overvalued?
According to Wall Street analysts Cambridge Cognition Holdings Plc’s price is currently Overvalued.
Does Cambridge Cognition Holdings Plc pay dividends?
Cambridge Cognition Holdings Plc does not currently pay dividends.
What is Cambridge Cognition Holdings Plc’s EPS estimate?
Cambridge Cognition Holdings Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cambridge Cognition Holdings Plc have?
Cambridge Cognition Holdings Plc has 54,037,327 shares outstanding.
What happened to Cambridge Cognition Holdings Plc’s price movement after its last earnings report?
Cambridge Cognition Holdings Plc reported an EPS of -€0.019 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cambridge Cognition Holdings Plc?
Currently, no hedge funds are holding shares in DE:1M7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cambridge Cognition Holdings Plc
Cambridge Cognition Holdings Plc is a neuroscience technology company focused on developing and globally marketing sophisticated cognitive testing solutions for use in clinical settings. The firm operates internationally, serving clients in the United States, United Kingdom, and European Union, among other regions. Its extensive product portfolio includes CANTAB Recruit, an online platform designed to help pharmaceutical and biotechnology companies efficiently identify and onboard eligible participants for clinical trials, particularly in high-need therapeutic areas such as Alzheimer's disease. For broader pharmaceutical research, CANTAB Connect offers digital cognitive assessment tools applicable across all clinical trial phases (I-IV) and various medical fields. Additionally, the Cognition Kit is a digital health platform that utilizes wearable and smartphone applications to collect data, aiming to boost patient involvement, validate treatment efficacy, and deepen understanding of diseases and individual responses to medication. Other specialized offerings include CANTAB Connect Research, advanced software providing precise digital metrics for cognitive function in brain research; CANTAB Mobile, a touchscreen memory test frequently used in clinical studies pertaining to Alzheimer's disease; and CANTAB BrainHealth, an online digital assessment tool for monitoring mental well-being and cognitive performance in professional environments. The company also provides CANTAB Insight, a medical device for evaluating an individual's cognitive health, and NeuroVocalix, a secure platform enabling automated administration and scoring of validated verbal cognitive assessments. Beyond its technological products, Cambridge Cognition furnishes a suite of expert consultancy and operational management services tailored to enhance clinical trials and cognitive research. These services encompass neuroscience and technical advice, study design, data analysis, comprehensive study and data management, and the provision of insightful reports and interpretations. Cambridge Cognition Holdings Plc was established in 2012 and is headquartered in Cambridge, United Kingdom.